Although both of these anti-cancer drugs counteract the production of detrimental cytokines, including IL-6, IL-8 and MCP-1 [21,25], neither ET743 nor PM01183 has yet been evaluated as able to limit the progression of cancer cachexia. Here, CXCL8 is linked to cancer.